Company intelligence / Profile preview

adyn

Claymont, Delaware, United Statesadyn.com ↗

Ownership: Private
Development stage: Commercial

Overview

adyn’s flagship product, The Birth Control Test, is the first at-home test designed to prevent birth control side effects by analyzing an individual’s hormone levels and genetic risks. It enables personalized contraceptive recommendations with the goal of minimizing adverse reactions. Early results indicate that 70% of initial users were informed of personal medical risks associated with certain prescriptions; 7.5% were saved from potentially life-threatening side effects

Therapeutic areas: Women's Health
Modalities: Diagnostic testDevice (at-home testing kit)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on adyn.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adyn.

Explore the full profile